BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18412875)

  • 21. In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod.
    Alarcon I; Carrera C; Alos L; Palou J; Malvehy J; Puig S
    J Am Acad Dermatol; 2014 Jul; 71(1):49-55. PubMed ID: 24725478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical imiquimod therapy for lentigo maligna.
    Mahoney MH; Joseph MG; Temple C
    Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
    Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
    J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periocular lentigo maligna treated with imiquimod.
    O'Neill J; Ayers D; Kenealy J
    J Dermatolog Treat; 2011 Apr; 22(2):109-12. PubMed ID: 20666668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
    Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
    Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
    Actas Dermosifiliogr; 2022 Apr; 113(4):T407-T412. PubMed ID: 35623739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lentigo maligna: review of salient characteristics and management.
    Kallini JR; Jain SK; Khachemoune A
    Am J Clin Dermatol; 2013 Dec; 14(6):473-80. PubMed ID: 24019181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.
    Erickson C; Miller SJ
    Int J Dermatol; 2010 May; 49(5):482-91. PubMed ID: 20534080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imiquimod use in the treatment of lentigo maligna.
    Junkins-Hopkins JM
    J Am Acad Dermatol; 2009 Nov; 61(5):865-7. PubMed ID: 19836644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lentigo maligna: current concepts in diagnosis and management.
    Walling HW
    G Ital Dermatol Venereol; 2009 Apr; 144(2):149-55. PubMed ID: 19357622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
    Donigan JM; Hyde MA; Goldgar DE; Hadley ML; Bowling M; Bowen GM
    JAMA Dermatol; 2018 Aug; 154(8):885-889. PubMed ID: 29847610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
    Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
    Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Wolf IH; Cerroni L; Kodama K; Kerl H
    Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of lentigo maligna with topical imiquimod.
    Naylor MF; Crowson N; Kuwahara R; Teague K; Garcia C; Mackinnis C; Haque R; Odom C; Jankey C; Cornelison RL
    Br J Dermatol; 2003 Nov; 149 Suppl 66():66-70. PubMed ID: 14616356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amelanotic lentigo maligna managed with topical imiquimod.
    Lapresta A; García-Almagro D; Sejas AG
    J Dermatol; 2012 May; 39(5):503-5. PubMed ID: 21973079
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
    Michalopoulos P; Yawalkar N; Brönnimann M; Kappeler A; Braathen LR
    Br J Dermatol; 2004 Oct; 151(4):903-6. PubMed ID: 15491436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [How I treat ... lentigo maligna by topical imiquimod].
    Bourguignon R; Paquet P; Quatresooz P; Piérard GE
    Rev Med Liege; 2005 Sep; 60(9):691-4. PubMed ID: 16265961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases.
    de Troya-Martín M; Frieyro-Elicegui M; Fúnez Liébana R; Aguilar Bernier M; Fernández-Canedo NI; Blázquez Sánchez N
    Dermatol Surg; 2008 Nov; 34(11):1561-6. PubMed ID: 18798748
    [No Abstract]   [Full Text] [Related]  

  • 40. Remission of extensive lentigo maligna after treatment with imiquimod.
    Piazza CD; Sampaio SA
    An Bras Dermatol; 2009; 84(1):82-4. PubMed ID: 19377765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.